Minerva Neurosciences | NERV - Operating Profit


Minerva Neurosciences reported $-21.85M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Adma Biologics USD 50.29M 12.46M Mar/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
AstraZeneca USD 3.16B 3.95B Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 840M 2.72B Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 667M 4.32B Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
Takeda JPY 201.42B 215.04B Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024